Ultragenyx Reports Second Quarter 2016 Financial Results and Corporate Update
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/24/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- Needham Starts NeoVolta (NEOV) at Buy
- NextEra to discuss paying about $76 per share for Dominion, Bloomberg News reports
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Campbell Soup (CPB) Declares $0.39 Quarterly Dividend; 7.7% Yield
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
Piper Jaffray Raises Price Target on Ultragenyx Pharma (RARE) to $82; Reiterates Overweight
August 9, 2016 8:53 AM EDTPiper Jaffray reiterated an Overweight rating on Ultragenyx Pharma (NASDAQ: RARE), and raised the price target to $82.00 (from $70.00), following the company's 2Q earnings report.
Analyst Steven Breazzano commented, "After the close, RARE reported 2Q earnings and provided an... More
Ultragenyx Pharma (RARE) Misses Q2 EPS by 2c
August 8, 2016 4:32 PM EDTUltragenyx Pharma (NASDAQ: RARE) reported Q2 EPS of ($1.46), $0.02 worse than the analyst estimate of ($1.44).
For earnings history and earnings-related data on Ultragenyx Pharma (RARE) click here.
... More